ERIC SCHAFER to Neoplasms
This is a "connection" page, showing publications ERIC SCHAFER has written about Neoplasms.
Connection Strength
0.508
-
A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer. 2018 08; 65(8):e27066.
Score: 0.214
-
Hispanic ethnicity as a risk factor for requiring glucarpidase rescue in pediatric patients receiving high-dose methotrexate. Am J Hematol. 2018 02; 93(2):E40-E42.
Score: 0.208
-
What Is the Expected Clearance of Methotrexate? A Therapeutic Drug Monitoring Reference Guide for High-Dose Methotrexate Use in Pediatric Malignancies. Pediatr Blood Cancer. 2025 Jul; 72(7):e31744.
Score: 0.087